Who are Solifenacin succinate treatment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Toviaz (Fesoterodine), Indacaterol/glycopyrronium, Oxybutynin chloride, extended-release, Albuterol, ipratropium bromide, Drug: ipratropium (AtroventTM), Solifenacin PO.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/solifenacin-succinate-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Solifenacin succinate treatment — Competitive Intelligence Brief

Solifenacin succinate treatment (Solifenacin succinate treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscarinic M3 receptor antagonist. Area: Urology.

marketed Muscarinic M3 receptor antagonist M3 muscarinic acetylcholine receptor Urology Small molecule Live · refreshed every 30 min

Target snapshot

Solifenacin succinate treatment (Solifenacin succinate treatment) — Barrie Urology Associates. Solifenacin succinate is a muscarinic M3 receptor antagonist that reduces involuntary bladder muscle contractions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Solifenacin succinate treatment TARGET	Solifenacin succinate treatment	Barrie Urology Associates	marketed	Muscarinic M3 receptor antagonist	M3 muscarinic acetylcholine receptor
Toviaz (Fesoterodine)	Toviaz (Fesoterodine)	Weill Medical College of Cornell University	marketed	Muscarinic M3 receptor antagonist	M3 muscarinic acetylcholine receptor
Indacaterol/glycopyrronium	Indacaterol/glycopyrronium	Orion Corporation, Orion Pharma	marketed	Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination)	Beta-2 adrenergic receptor; M3 muscarinic acetylcholine receptor
Oxybutynin chloride, extended-release	Oxybutynin chloride, extended-release	US Department of Veterans Affairs	marketed	Anticholinergic agent	M3 muscarinic acetylcholine receptor
Albuterol, ipratropium bromide	Albuterol, ipratropium bromide	Children's Hospital of Philadelphia	marketed	Combination bronchodilator (beta-2 agonist + anticholinergic)	Beta-2 adrenergic receptor; M3 muscarinic acetylcholine receptor
Drug: ipratropium (AtroventTM)	Drug: ipratropium (AtroventTM)	AstraZeneca	marketed	Anticholinergic bronchodilator	M3 muscarinic acetylcholine receptor
Solifenacin PO	Solifenacin PO	Seattle Urology Research Center	marketed	Muscarinic M3 receptor antagonist	M3 muscarinic acetylcholine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Muscarinic M3 receptor antagonist class)

Astellas Pharma Inc · 2 drugs in this class
Barrie Urology Associates · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Pfizer · 1 drug in this class
Seattle Urology Research Center · 1 drug in this class
Weill Medical College of Cornell University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Solifenacin succinate treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/solifenacin-succinate-treatment. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab